Emerging integrated nanoclay-facilitated drug delivery system for papillary thyroid cancer therapy.

Yi Zhang,Linfeng Mao,Shi Chang,Peng Huang,Mei Long,Aidong Tang,Yuehua Hu,Huaming Yang

doi:10.1038/srep33335

Abstract

Nanoclay can be incorporated into emerging dual functional drug delivery systems (DDSs) to promote efficiency in drug delivery and reduce the toxicity of doxorubicin (DOX) used for thyroid cancer treatment. This paper reports the expansion of the basal spacing of kaolinite nanoclay was expanded from 0.72 nm to 0.85 nm, which could provide sufficiently spacious site for hosting doxorubicin molecules and controlling the diffusion rate. A targeted design for papillary thyroid cancer cells was achieved by introducing KI, which is consumed by the sodium-iodide symporter (NIS). As indicated by MTT assays, confocal laser scanning microscopy and bio-TEM observations, methoxy-intercalated kaolinite (KaolinMeOH) exhibited negligible cytotoxicity against papillary thyroid cancer cells. By contrast, DOX-KaolinMeOH showed dose-dependent therapeutic effects in vitro, and KI@DOX-KaolinMeOH was found to act as a powerful targeted therapeutic drug. Furthermore, active and passive targeting strategies played a role in the accumulation of the drug molecules, as verified by an in vivo bio-distribution analysis.

Highlights

Nanoclay can be incorporated into emerging dual functional drug delivery systems (DDSs) to promote efficiency in drug delivery and reduce the toxicity of doxorubicin (DOX) used for thyroid cancer treatment
A number of targeted DDSs based on carrier modification, drug molecule loading and the assembly of specific targeting assembly have been used in thyroid cancer treatment[22,23,24,25,26]
Tests of the design described above revealed that this targeted KI@DOX-KaolinMeOH DDS is highly effective for papillary thyroid cancer treatment

Summary

Introduction

Nanoclay can be incorporated into emerging dual functional drug delivery systems (DDSs) to promote efficiency in drug delivery and reduce the toxicity of doxorubicin (DOX) used for thyroid cancer treatment. We used methoxy-intercalated kaolinite (KaolinMeOH) as a typical nanoclay container for the targeted delivery of DOX to cancer tissues with correspondingly diminished its side effects. In addition to the procedures described above, PEGylation was applied to improve the permeability, stability and anti-corrosion of these nanocomposites in vivo and to minimize macrophage phagocytosis We believe that this combination of techniques is highly meaningful because it can give rise to an effective targeted DDS for thyroid cancer treatment (Fig. 1)

Methods

Results

Conclusion